Overview
This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.
Eligibility
Inclusion Criteria:
- Participant who is being treated with ONO-4538 as monotherapy or in Combination with Other Therapies in clinical trials
- Participant who is eligible for ONO-4538 monotherapy or in combination with other therapies as per the clinical trials, and/or investigator-assessed clinical benefit
Exclusion Criteria:
- Participant judged to be incapable of providing consent for reasons such as concurrent dementia
- Participant judged by the investigator to be inappropriate as participants of this study